DUBLIN--(BUSINESS WIRE)--The "Osteogenesis Imperfecta - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.
Osteogenesis Imperfecta - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Osteogenesis Imperfecta (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Osteogenesis Imperfecta (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteogenesis Imperfecta and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 1 and 5 respectively.
Key Topics Covered:
- Osteogenesis Imperfecta - Overview
- Osteogenesis Imperfecta - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Osteogenesis Imperfecta - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Osteogenesis Imperfecta - Companies Involved in Therapeutics Development
- Amgen Inc
- Bone Therapeutics SA
- Genzyme Corp
- Mereo Biopharma Group Plc
For more information about this report visit https://www.researchandmarkets.com/research/2k5fkv/osteogenesis